BIDIL Drug Patent Profile
✉ Email this page to a colleague
When do Bidil patents expire, and when can generic versions of Bidil launch?
Bidil is a drug marketed by Azurity and is included in one NDA.
The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BIDIL?
- What are the global sales for BIDIL?
- What is Average Wholesale Price for BIDIL?
Summary for BIDIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 6 |
| Drug Prices: | Drug price information for BIDIL |
| What excipients (inactive ingredients) are in BIDIL? | BIDIL excipients list |
| DailyMed Link: | BIDIL at DailyMed |
Pharmacology for BIDIL
| Drug Class | Arteriolar Vasodilator Nitrate Vasodilator |
| Physiological Effect | Arteriolar Vasodilation Vasodilation |
US Patents and Regulatory Information for BIDIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BIDIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BIDIL
See the table below for patents covering BIDIL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 0117528 | ⤷ Sign Up | |
| Australia | 7365900 | ⤷ Sign Up | |
| Canada | 2383974 | ⤷ Sign Up | |
| European Patent Office | 1212053 | ⤷ Sign Up | |
| Canada | 1308659 | METHODE DE REDUCTION DE LA MORTALITE ASSOCIEE A L'INSUFFISANCE CARDIAQUE CONGESTIVE FAISANT APPEL A L'HYDRALAZINE ET AU DINITRATE D'ISOSOBIDE (METHOD OF REDUCING MORTALITY ASSOCIATED WITH CONGESTIVE HEART FAILURE USING HYDRALAZINE AND ISOSORBIDE DINITRATE) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
